Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
BRIP1 Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | Q9BX63 |
| Other Accession | NP_114432 |
| Reactivity | Human, Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 140867 Da |
| Antigen Region | 132-163 aa |
| Gene ID | 83990 |
|---|---|
| Other Names | Fanconi anemia group J protein, Protein FACJ, ATP-dependent RNA helicase BRIP1, BRCA1-associated C-terminal helicase 1, BRCA1-interacting protein C-terminal helicase 1, BRCA1-interacting protein 1, BRIP1, BACH1, FANCJ |
| Target/Specificity | This BRIP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 132-163 amino acids from the N-terminal region of human BRIP1. |
| Dilution | WB~~1:1000 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | BRIP1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | BRIP1 (HGNC:20473) |
|---|---|
| Function | DNA-dependent helicase and 5' to 3' DNA helicase required for the maintenance of chromosomal stability (PubMed:11301010, PubMed:14983014, PubMed:16116421, PubMed:16153896, PubMed:36608669). Acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination (PubMed:14983014, PubMed:16153896). Involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1 (PubMed:14983014, PubMed:16153896). Involved in the repair of abasic sites at replication forks by promoting the degradation of DNA-protein cross-links: acts by catalyzing unfolding of HMCES DNA-protein cross-link via its helicase activity, exposing the underlying DNA and enabling cleavage of the DNA- protein adduct by the SPRTN metalloprotease (PubMed:16116421, PubMed:36608669). |
| Cellular Location | Nucleus. Cytoplasm |
| Tissue Location | Ubiquitously expressed, with highest levels in testis. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
BRIP1 is a member of the RecQ DEAH helicase family and interacts with the BRCT repeats of breast cancer, type 1 (BRCA1). The bound complex is important in the normal double-strand break repair function of breast cancer, type 1 (BRCA1).
References
Ucisik-Akkaya, E., et al. Mol. Hum. Reprod. 16(10):770-777(2010)
Bailey, S.D., et al. Diabetes Care (2010) In press :
Solyom, S., et al. Fam. Cancer (2010) In press :
Xie, J., et al. Oncogene 29(17):2499-2508(2010)
Smith, I.M., et al. ORL J. Otorhinolaryngol. Relat. Spec. 72(1):44-50(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
